Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin

• Status: Completed
• Trial end date: 2019-09-03
• Target enrollment: 0
• Participant gender: All

Summary

Some aspirin-treated patients have a blunted pharmacological response predisposing to clinical failure. The investigators hypothesize that the blunted response often results from increased rate of platelet production and some failures will be prevented by administering aspirin twice daily. The overall objective is to develop a valid method to quantify platelet production (without the use of radioactive isotopes) in order to examine the hypothesis that enhanced platelet production is a common cause of poor aspirin responsiveness in patients with atherothrombosis.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hamilton Health Sciences Corporation
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Healthy non-smoking volunteers;

• Age ≥ 18 years;

Exclusion Criteria:

• Allergy or intolerance to aspirin;

• Current pregnancy;

• Use of aspirin or drugs interfering with platelet function (NSAIDs, anticoagulants) within one week of study enrolment.